The FDA is Warning Users of This Daily Medication

Anyone who suffers from a chronic illness is likely to have a daily drug routine. Luckily, there are products available that can help reduce symptoms, prevent significant health problems, and allow you to live a pretty normal life. For instance, injectable insulin vials are considered forever living products for diabetes. 

However, the Food and Drug Administration (FDA) has recently issued a warning about one everyday medicine that you should be aware of.

Continue reading to find out which medication is being recalled owing to possible health risks.

1. What is a Mylan Pill and Why is it Recalled?

According to the FDA, Mylan Pharmaceuticals Inc. has recalled an Insulin Glargine injection which is sold in a 100 ml pill bottle. The product is supplied in a carton with 10 pill mL vials. Between December 9, 2021, and March 4, 2022, Mylan Specialty L.P. distributed the implicated items in the United States.

The NDC code 49502-393-80, batch code BF21002800, and the expiry date of August 2023 printed on the container in which it was sent identify recalled products. However, the recall is intended for unbranded bottles only. Therefore, customers with labeled bottles of Insulin Glargine are safe. 

According to the notification, Mylan Pharmaceuticals ordered the Mylan pill recall upon learning that some vials in the batch in question may be missing labels. As a result, children and adults with type 1 or type 2 diabetes who take the drug daily to enhance glycemic control may be at risk.

A label lacking on Insulin Glargine vials could result in a mix-up of products/strengths for patients undergoing treatment with far more than one type of insulin.

For example, both short and long-acting insulin could result in less effective glycemic control (either low or high blood sugar), resulting in serious complications,” the FDA warns.

2. What Should Be Done?

The FDA encourages all retailers to do an immediate inventory check for the recalled goods. If any are discovered, isolate them and stop distributing the batch.

Medical supply distributors should also check their inventory, isolate the recalled product, and stop selling it. In addition, they must also approach all their customers who have already obtained the product being recalled.

This will also include retail customers. Moreover, a detailed Excel filet of every potential buyer should be produced within 5 business days and sent to mylan5889@sedgwick.com.

This information will be used by Sedgwick (Stericycle) to notify your retail customers who received the problematic batch.

Fortunately, according to the FDA, no adverse medical occurrences linked to the recalls have yet been reported. In addition, customers with unlabeled vials should contact Stericycle at 1-888-912-7084 to demand a paperwork packet to return the goods to the firm.

Customers can call Viatris’ customer service hotline at 1-800-796-9526 on weekdays between 8 a.m. to 5 p.m. EST or drop an email to customer.service@viatris.com with general inquiries concerning the recall.

According to the FDA, anyone who has had health difficulties due to using the recalled product should contact their physician or healthcare provider right away.